To view enhanced content for this article go to http://www.medengine.com/Redeem/C037F060697B3BB9.
M. Kokki and M. Kuronen contributed equally.
Opioids are needed for postoperative pain in spine surgery patients, but opioid-induced constipation is a harmful adverse event. The aim of this clinical trial was to compare the use of a controlled-release oxycodone-naloxone combination product with oxycodone controlled-release tablets in these patients. The main outcome measure was the prevalence of constipation at 7 days postoperatively assessed with a Bowel Function Index questionnaire. A follow-up assessment at 21 days after surgery was also included.
A total of 180 patients undergoing spine surgery, 91 having preoperative opioids in use and 89 opioid-naïve, were randomized to receive twice-daily oxycodone 10 mg or oxycodone-naloxone 10/5 mg controlled-release tablets for the first 7 postoperative days. Patients were followed-up for 21 days after surgery.
At baseline, prevalence of constipation was common both in the opioid-naïve—25/87 (29%) and on-opioid groups 43/90 (48%) (P = 0.009). This increased at 7 days postoperatively with no difference between the groups, 54/89 with oxycodone and 54/88 with oxycodone-naloxone had constipation. At 21 days, constipation was less than in the baseline in both groups, in the opioid-naïve group the prevalence of constipation was 3/43 (7%) in patients with oxycodone-naloxone compared to 9/44 (21%) with oxycodone (effect size 0.68; P = 0.068). Both study compounds provided similar pain relief and were well tolerated.
In patients presented for back surgery, the prevalence of constipation was significantly higher than that in the community. In opioid-naïve subjects, oxycodone-naloxone was beneficial concerning constipation; but this was not distinguishable in subjects with chronic opioid use. The analgesic efficacy of oxycodone and oxycodone-naloxone was similar.
Trial registration: European Clinical Trials Database (EudraCT no. 2012-001816-42) and ClinicalTrials.gov database (Identifier: NCT02573922).
Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182:11–8. CrossRef
The Report of the International Narcotics Control Board for 2015 (E/INCB/2015/1), United Nations. https://www.incb.org/documents/Narcotic-Drugs/Technical-Publications/2015/NAR-tech_pub_2015.pdf. Accessed 21 Oct 2016.
Kokki H, Kokki M, Sjövall S. Oxycodone for the treatment of post-operative pain. Expert Opin On Pharmacother. 2012;13:1045–58. CrossRef
Smith K, Hopp M, Mundin G, et al. Low absolute bioavailability of oral naloxone in healthy subjects. Int J Clin Pharmacol Therap. 2012;50:360–7. CrossRef
Helakorpi S, Pajunen T, Jallinoja P, Virtanen S, Uutela A. Health behaviour and health among the Finnish adult population, Spring 2010. National Institute for Health and Welfare (THL), Report 15/2011, 203 pages. Helsinki 2011. ISBN 978-952-245-472-0 (print), ISBN 978-952-245-473-7 (pdf). https://www.thl.fi/documents/10531/95613/Raportti%202011%2015.pdf. Accessed 15 Aug 2016.
Summary of product characteristics Lyrica. http://www.ema.europa.eu/docs/fi_FI/document_library/EPAR_-_Product_Information/human/000546/WC500046602.pdf. Accessed 15 Aug 2016.
Summary of product characteristics Neurontin. http://spc.fimea.fi/indox/nam/html/nam/humspc/7/10796177.pdf. Accessed 15 Aug 2016.
Coyne K, LoCasale R, Datto C, Sexton C, Yeomans K, Tack J. Opioid-induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany and the UK: descriptive analysis of baseline patient-reported outcomes and retrospective chart review. Clinicoecon Outcomes Res. 2014;6:269–81. CrossRefPubMedPubMedCentral
Poelaert J, Koopmans-Klein G, Dioh A, et al. Treatment with prolonged-release oxycodone/naloxone improves pain relief and opioid-induced constipation compared with prolonged-release oxycodone in patients with chronic severe pain and laxative-refractory constipation. Clin Ther. 2015;37:784–92. CrossRefPubMed
- Opioid-Induced Bowel Dysfunction in Patients Undergoing Spine Surgery: Comparison of Oxycodone and Oxycodone-Naloxone Treatment
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
e.Med Kampagnen-Visual, Mail Icon II